POSTERIOR TRACTIONAL MEMBRANES FOLLOWING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR RETINOPATHY OF PREMATURITY

Retin Cases Brief Rep. 2022 Sep 1;16(5):576-580. doi: 10.1097/ICB.0000000000001036.

Abstract

Purpose: To report two cases of tractional membrane formation following treatment with anti-vascular endothelial growth factor therapy in infants with Stage-3 retinopathy of prematurity.

Methods: Retrospective review of electronic medical record for historical information, clinical examination documentation, and imaging from fundus photography, retinal ultrasonography, and fluorescein angiography.

Results: Two patients with Stage-3 retinopathy of prematurity, previously treated with laser therapy and intravitreal bevacizumab, were referred to our institution for tractional membranes. The first case is of a male infant with Zone-II disease that progressed to Stage 4A with evidence of inferotemporal tractional retinal detachment only in the left eye. The second case is of a male infant with stable Zone-I disease with an epiretinal membrane in the left eye.Pars plicata vitrectomy and membranectomy were required for both cases because of the concern for subsequent tractional retinal detachment.

Conclusion: Formation of tractional retinal membranes has been associated with anti-vascular endothelial growth factor therapy. These cases describe the formation of posterior tractional membranes after anti-vascular endothelial growth factor therapy. This potential ocular outcome should be considered when determining treatment plans for retinopathy of prematurity.

MeSH terms

  • Angiogenesis Inhibitors / adverse effects
  • Bevacizumab / adverse effects
  • Endothelial Growth Factors / therapeutic use
  • Humans
  • Infant
  • Infant, Newborn
  • Intravitreal Injections
  • Male
  • Retinal Detachment* / diagnosis
  • Retinal Detachment* / drug therapy
  • Retinal Detachment* / etiology
  • Retinopathy of Prematurity* / surgery
  • Retrospective Studies
  • Vascular Endothelial Growth Factor A

Substances

  • Angiogenesis Inhibitors
  • Endothelial Growth Factors
  • Vascular Endothelial Growth Factor A
  • Bevacizumab